292 related articles for article (PubMed ID: 28357069)
1. Efficacy of a potassium-competitive acid blocker for improving symptoms in patients with reflux esophagitis, non-erosive reflux disease, and functional dyspepsia.
Asaoka D; Nagahara A; Hojo M; Matsumoto K; Ueyama H; Matsumoto K; Izumi K; Takeda T; Komori H; Akazawa Y; Shimada Y; Osada T; Watanabe S
Biomed Rep; 2017 Feb; 6(2):175-180. PubMed ID: 28357069
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease.
Gotoh Y; Ishibashi E; Honda S; Nakaya T; Noguchi C; Kagawa K; Murakami K
Medicine (Baltimore); 2020 Mar; 99(11):e19520. PubMed ID: 32176102
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux.
Akiyama J; Hosaka H; Kuribayashi S; Moriyasu S; Hisada Y; Okubo H; Watanabe K; Imbe K; Nagata N; Kojima Y; Yokoi C; Uemura N; Shimoyama Y; Kawamura O; Yamada M; Kusano M
Digestion; 2020; 101(2):174-183. PubMed ID: 30897577
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: significance of frequency scale for the symptom of GERD (FSSG) on decision of treatment strategy.
Miyamoto M; Manabe N; Haruma K
Intern Med; 2010; 49(15):1469-76. PubMed ID: 20686276
[TBL] [Abstract][Full Text] [Related]
5. The Ameliorating Effect of Switching to Vonoprazan: A Novel Potassium-Competitive Acid Blocker in Patients with Proton Pump Inhibitor Refractory Non-Erosive Reflux Disease.
Abe Y; Koike T; Saito M; Okata T; Nakagawa K; Hatta W; Asanuma K; Uno K; Asano N; Imatani A; Masamune A
Digestion; 2021; 102(3):480-488. PubMed ID: 32062650
[TBL] [Abstract][Full Text] [Related]
6. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan.
Furuta T; Shimatani T; Sugimoto M; Ishihara S; Fujiwara Y; Kusano M; Koike T; Hongo M; Chiba T; Kinoshita Y;
J Gastroenterol; 2011 Nov; 46(11):1273-83. PubMed ID: 21861141
[TBL] [Abstract][Full Text] [Related]
7. [A comparison of clinical characteristics between non-erosive reflux disease and reflux esophagitis].
Pan HY; Xiang XL; Lyu SZ; Xie XP; Hou XH
Zhonghua Nei Ke Za Zhi; 2016 Jul; 55(7):510-4. PubMed ID: 27373284
[TBL] [Abstract][Full Text] [Related]
8. The Therapeutic and Diagnostic Value of 2-week High Dose Proton Pump Inhibitor Treatment in Overlapping Non-erosive Gastroesophageal Reflux Disease and Functional Dyspepsia Patients.
Kriengkirakul C; Patcharatrakul T; Gonlachanvit S
J Neurogastroenterol Motil; 2012 Apr; 18(2):174-80. PubMed ID: 22523726
[TBL] [Abstract][Full Text] [Related]
9. More severe upper gastrointestinal symptoms associated with non-erosive reflux disease than with erosive gastroesophageal reflux disease during maintenance proton pump inhibitor therapy.
Kusano M; Hosaka H; Kawamura O; Kawada A; Kuribayashi S; Shimoyama Y; Yasuoka H; Mizuide M; Tomizawa T; Sagawa T; Sato K; Yamada M
J Gastroenterol; 2015 Mar; 50(3):298-304. PubMed ID: 24919745
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for functional dyspepsia, erosive and non-erosive gastroesophageal reflux disease: A cross-sectional study.
Caballero-Mateos AM; López-Hidalgo JL; Torres-Parejo Ú; Hernández-González JM; Quintero-Fuentes MD; Caballero-Plasencia AM; Redondo-Cerezo E
Gastroenterol Hepatol; 2023; 46(7):542-552. PubMed ID: 36584749
[TBL] [Abstract][Full Text] [Related]
11. A systematic review and meta-analysis of the efficacy of vonoprazan for proton pump inhibitor-resistant gastroesophageal reflux disease.
Simadibrata DM; Lesmana E; Fass R
J Gastroenterol Hepatol; 2024 May; 39(5):796-805. PubMed ID: 38263507
[TBL] [Abstract][Full Text] [Related]
12. Differences Between Patients with Heartburn Refractory to Vonoprazan and Those Refractory to Proton Pump Inhibitors.
Matsumura T; Sonoda M; Okimoto K; Dao HV; Takahashi S; Akizue N; Horio R; Goto C; Kurosugi A; Kaneko T; Ohta Y; Taida T; Kikuchi A; Fujie M; Kato J; Kato N
Dig Dis Sci; 2024 Jun; 69(6):2132-2139. PubMed ID: 38622462
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Vonoprazan for Proton Pump Inhibitor-Resistant Reflux Esophagitis.
Hoshino S; Kawami N; Takenouchi N; Umezawa M; Hanada Y; Hoshikawa Y; Kawagoe T; Sano H; Hoshihara Y; Nomura T; Iwakiri K
Digestion; 2017; 95(2):156-161. PubMed ID: 28190016
[TBL] [Abstract][Full Text] [Related]
14. A single-center retrospective study on epidemiological and Traditional Chinese Medicine syndrome characteristics of 21010 patients with reflux/heartburn symptoms.
Yanping T; Peicai LI; Xi L; Lei L; Yanxia G; Xiaodong W; Lina L; Li Y
J Tradit Chin Med; 2023 Jun; 43(3):574-581. PubMed ID: 37147760
[TBL] [Abstract][Full Text] [Related]
15. Vonoprazan 10 mg daily is effective for the treatment of patients with proton pump inhibitor-resistant gastroesophageal reflux disease.
Shinozaki S; Osawa H; Hayashi Y; Sakamoto H; Kobayashi Y; Lefor AK; Yamamoto H
Biomed Rep; 2017 Sep; 7(3):231-235. PubMed ID: 28894571
[TBL] [Abstract][Full Text] [Related]
16. [Symptom overlaps between functional heartburn, functional dyspepsia, and irritable bowel syndrome].
Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 May; 45(3):489-92. PubMed ID: 24941825
[TBL] [Abstract][Full Text] [Related]
17. Factors Associated with Overlap between Functional Dyspepsia and Nonerosive Reflux Disease in Endoscopy-based Helicobacter pylori-uninfected Japanese Health Checkup Participants: A Prospective, Multicenter Cross-sectional Study.
Fujita T; Umegaki E; Masuda A; Kobayashi M; Yamazaki Y; Terao S; Sanuki T; Okada A; Murakami M; Watanabe A; Obata D; Yoshinaka H; Kutsumi H; Azuma T; Kodama Y
Intern Med; 2024 Mar; 63(5):639-647. PubMed ID: 37438139
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of vonoprazan for 24-week maintenance therapy of patients with healed reflux esophagitis refractory to proton pump inhibitors.
Mizuno H; Yamada K; Minouchi K; Kamiyamamoto S; Hinoue Y
Biomed Rep; 2018 Feb; 8(2):148-155. PubMed ID: 29435273
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics of elderly patients with proton pump inhibitor-refractory non-erosive reflux disease from the G-PRIDE study who responded to rikkunshito.
Sakata Y; Tominaga K; Kato M; Takeda H; Shimoyama Y; Takeuchi T; Iwakiri R; Furuta K; Sakurai K; Odaka T; Kusunoki H; Nagahara A; Iwakiri K; Furuta T; Murakami K; Miwa H; Kinoshita Y; Haruma K; Takahashi S; Watanabe S; Higuchi K; Fujimoto K; Kusano M; Arakawa T;
BMC Gastroenterol; 2014 Jul; 14():116. PubMed ID: 24990161
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Vonoprazan for 48-Week Maintenance Therapy of Patients with Healed Reflux Esophagitis.
Mizuno H; Nishino M; Yamada K; Kamiyamamoto S; Hinoue Y
Digestion; 2020; 101(4):411-421. PubMed ID: 31129668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
